Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | HRH2 | P25021 | 13/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061658 | 0.82 | HTR2A (0.46) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL4058347 | 0.81 | HRH2 (0.58) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL5748447 | 0.78 | HRH2 (0.43) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL13768719 | 0.73 | HRH2 (0.58) | HTR2AHTR2CHTR2BHRH2SLC6A4 | |
| SCHEMBL4053254 | 0.70 | CNR1 (0.47) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4056351 | 0.70 | NOS2 (0.46) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL4056205 | 0.69 | HTR6 (0.48) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL24567395 | 0.68 | OPRM1 (0.45) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6159305 | 0.67 | HRH2 (0.48) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL991263 | 0.67 | HRH1 (0.73) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622480-B2 | Selective H1 histamine receptor antagonists; bronchial asthma, allergic rhinitis, conjunctivitis, dermatitis, urticaria and other allergic diseases; e.g. 3-(4-[1-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]piperidin-1-ylmethyl)benzoic acid | LABORATORIOS ALMIRALL S.A. (ES) | 2009-11-24 | — | — | US | disclosed |
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | HRH2, HRH1, HRH4 | HTR2A 83/4885HTR2C 190/4885HTR2B 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.